DRUG QUANTITY MANAGEMENT POLICY – PER DAYS

POLICY: Inflammatory Conditions – Siliq Drug Quantity Management Policy – Per Days
- Siliq® (brodalumab subcutaneous injection – Valeant)

REVIEW DATE: 12/19/2022

OVERVIEW

Siliq, an interleukin (IL)-17A antagonist, is indicated for treatment of adults with moderate-to-severe **plaque psoriasis** who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.[1] In the pivotal trial, patients were assessed for a response at Week 12.

Dosing

The recommended dose of Siliq is 210 mg administered by subcutaneous injection at Weeks 0, 1, and 2, followed by 210 mg every 2 weeks.[1]

Availability

Siliq is supplied in a carton of two 210 mg/1.5 mL single-dose prefilled syringes.[1]

POLICY STATEMENT

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of Siliq, and to manage potential premature dose escalation. If the Drug Quantity Management rule is not met at the point of service, coverage will be determined by the Criteria below. All approvals are provided for the duration noted below.

Automation: None.

Drug Quantity Limits

Product	Strength and Form	Retail Maximum Quantity per 28 Days	Home Delivery Maximum Quantity per 84 Days
Siliq® (brodalumab subcutaneous injection)	210 mg/1.5 mL prefilled syringe	2 prefilled syringes (420 mg)	6 prefilled syringes (1,260 mg)

CRITERIA

1. If the patient is initiating treatment or requires additional induction dosing, as verified by the absence of claims for Siliq in the past 130 days, approve a one-time override for 4 prefilled syringes (840 mg) at retail or 8 prefilled syringes (1,680 mg) at home delivery.
Note: The override at home delivery allows for initiation dosing at Week 0, Week 1, and Week 2 and then 210 mg once every 2 weeks at Weeks 4, 6, 8, 10, and 12.

REFERENCES

1. Siliq® subcutaneous injection [prescribing information]. Bridgewater, NJ: Valeant, February 2017.